Arta M Monjazeb,Jeremy Katz,Jiwon Sarah Park,Robert D Boutin,Robert J Canter,Robert J Steffner,Yves-Paul Nakache
Department of Orthopaedic Surgery, Columbia University Medical Center, New York, New York.,Division of Radiation Oncology, Department of Radiation Oncology, University of California Davis Medical Center, Sacramento, California.,Division of Radiology, Department of Radiology, University of California Davis Medical Center, Sacramento, California.,Division of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California.,Division of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California. Electronic address: rjcanter@ucdavis.edu.,University of California Davis School of Medicine, Sacramento, California.
Publication
Summary
In our cohort, 20 patients were managed with surveillance, 24 patients with surgery, and three patients with other approaches. Clinical and tumor characteristics between treatment groups were not significantly different. With a median follow-up of 35.7 mo, there was one complete regression, five partial regressions, and 13 stable diseases among the surveillance group. Only one patient under observation progressed, crossing over to surgical resection. Among 24 patients managed with surgery, 13 patients developed local recurrence. Kaplan-Meier analysis revealed a statistically superior progression-free survival in the surveillance group (P = 0.001).This retrospective analysis adds to the growing body of evidence that observation of desmoid tumors is safe and effective with high rates of stable disease.
Stay Up to Date as We Uncover More About Desmoid Tumors
